Press Releases

• Firm co-develops Animal Vaccine with NSTDA in a bid to become Biotech Leader in ASEAN
• Shows a Strong 49.8% Net Profit Growth for first 9-month period
• Food Industry & Pandemic Prevention keep fueling its Business Expansion

Bioscience Animal Health Plc. (BIS), a leading Animal Drugs and Vaccine provider, prepares for IPO to invest in a Vaccine Joint-Development with National Bio Technology Center and National Science Technology Development Agency (NSTDA). Bioscience aims to capitalize on its Full-service Drug & Vaccine businesses and Large customer base in the Food & Meat Export Industry. It plans to expand into ASEAN markets.

Mr. Vanchai Lerthirunrussamee, Chairman, Bioscience Animal Health Plc. (BIS) says that “Bioscience Animal Health Group is a leading Drug and Vaccine provider for Livestock and Pets. We are trusted for 18 years by many global drug companies and international-standard food and farm companies. We distribute over 446 Drugs/ Vaccines/ Animal products from many global brands and our owned brands. BIS has a large customer base in the Food Industry, as Thailand is a Global Kitchen. Ministry of Industry expects that Food Export will reach 1 Trillion Baht this year, whereas there are over 21 million tons of meat produced each year for domestic and export.

“Bioscience” aims to be one of leading providers in Bio Tech Industry, a new S- Curve industry. We focus on developing animal vaccine and integrated products for Livestocks and Pets. Livestock is one of Thailand’s Major industries with increasingly high market value. Faced with many pandemic and diseases outbreak and High-standard Hygienic requirements from global markets, Drugs, Vaccine and Test Kits products are becoming more essential to the food companies.”

Mr. Thanawat Kongcharoensombat, Vet, Chief Executive Officer, Bioscience Animal Health Plc. (BIS) says that “Bioscience Animal Health” was founded by a group of Veterinarian Management with Veterinarian Expertise as well as Business Acumen. The Group has expanded continuously and has 5 subsidiaries to focus on serving its particular growing market segment.

“Now, Bioscience is one of Thailand’s leaders in Integrated Animal Health Products, representing many global brands from 13 countries such as USA, Europe, China, South Korea. We also have our Owned Brand products and GMP-certified manufacturing factory. Our 5 Product Groups are 1. Animal Health Product: Drugs & Vaccine 2. Nutrition Product: Pre-Biotics, Pro-Biotics and Herbs 3. Diagnostic Product: Test Kits 4. Complete Feed Product 5. Ingredient Product

“Bioscience” has Revenue for 2019, 2020 and 2021 of 1,525.99 million baht, 1,884.27 million baht and 1,783.71 million baht, accordingly. Revenue for 9-month period of 2021 and 2022 are 1,288.36 million baht and 1,418.31 million baht with Net Profit in 2019-2021 equal 29.78 million baht, 61.35 million baht and 54.45 million baht, showing a Net Profit Margin of 1.95%, 3.26% and 3.05%. Its Net Profit for 9-month period ending Septermber 2021 and 2022 are 35.21 million baht and 52.76 million baht, accordingly, showing a Net Profit Margin of 2.73% and 3.72%. This shows a Strong Business Improvement, in contrast to the economy decline. With Over 18 years in Business, Strong accumulated customers relationship with both global and local companies, which are key business success factors. Its Board of Director consists of well-trusted senior management from both government, health care and private sectors, therefore ensuring good corporate governance and agile professional business management.

“Bioscience plans to raise funds in the stock market in order to invest in the Pig Vaccine Research & Development project with NSTDA. This Vaccine will not only be Thailand’s First Vaccine Development but also reduces High Importing Costs and Reliance on imported vaccines. Importantly, it will enable the Company to become one of leading Biotech Firms. Besides, BIS plans to expand production capacity for Vitamins and Food Supplements for Animals. We expect the Food industry to resume expansion as global and Thai economies expand again soon after the Corona-virus situation improve.”

Bioscience focuses on doing Research and Development projects with Thailand’s leading Research Houses. The Company successfully co-develops an ASF Animal Vaccine. In addition, the Company co-develops Thailand’s First Covid-19 Real Time PCR Test Kits for both Human and ANaimals, approved by Thai FDA. This effort will enable the Company to grow sustainably.

Bioscience Animal Health Plc. (BIS) has a registered capital of 157 million baht and paid capital of 110 million baht, with plan to offer 94 million shares for IPO (Par Value 0.50 baht/ share) to public investors for listing in mai. The Company plans to become of driving forces in the Bio Tech Industry in Thailand and ASEA to ensure sustainable growth.